Navigation Links
Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results
Date:8/6/2009

gen, and the results demonstrate the potential for Contrave to help patients in their battle against obesity," said Mike Narachi, President and CEO of Orexigen. "These results highlight the benefits of Contrave, a novel combination therapy that was specifically designed to address the behavior and reward pathways in the brain that impact one's ability to initiate and sustain weight loss."

Recent Highlights

Contrave

Orexigen announced that the three remaining Phase 3 trials in the Contrave Obesity Research, or COR, program met their co-primary endpoints. Key top-line data from the COR Phase 3 program include the following:

  • 48.0% and 56.3% of patients on Contrave32(1) in COR-I (NB-301) and COR-II (NB-303) lost at least 5% of their body weight after 56 weeks, approximately three times the placebo categorical response rates of 16.4% and 17.1%, respectively (ITT, p<0.001).
  • Contrave patients in COR-I and COR-II on Contrave32 had mean weight loss of 6.1% and 6.4% after 56 weeks, compared to 1.3% and 1.2% on placebo, respectively (ITT, p<0.001).
  • In the COR-Diabetes (NB-304) trial, 44.5% of patients on Contrave32 lost greater than or equal to 5% of their body weight after 56 weeks, more than double the 18.9% of patients on placebo (p<0.001). Contrave patients also showed a 0.6% reduction in HbA1c from baseline, compared to a 0.1% reduction in placebo. This difference of 0.5% is clinically and statistically significant (ITT, p<0.001).
  • Key secondary endpoints met in the COR Phase 3 program included significant improvements in cardiovascular and metabolic risk factors such as waist circumference, visceral fat, HDL cholesterol and triglycerides.
  • Additional analyses indicate that Contrave patients experienced reductions in the frequency and strength of food cravings and an increased ability to control their eati
    '/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Orexigen(R) Therapeutics Prices Public Offering of Common Stock
2. Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock
3. Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R)
4. Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer
5. Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors
6. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
7. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
8. Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 6
9. Quark Pharmaceuticals to Participate in IBCs Oligonucleotide Therapeutics: From Concept to Implementation Conference
10. United Therapeutics Corporation Reports Second Quarter 2009 Financial Results
11. Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... August 27, 2014 The Global and ... study on the current state of the Maleic Anhydride ... a basic overview of the industry, including definitions, applications ... domestic market analysis are provided with a focus on ... A comparison between the international and Chinese situation is ...
(Date:8/27/2014)... IQ Formulations , a leading manufacturer of ... of the Cystic Fibrosis Foundation. For an entire month ... led by TigerFitness.com in which 5 percent of the ... to the respected nonprofit organization. , Last year, ... Isla, a young girl fighting Cystic Fibrosis. The company ...
(Date:8/27/2014)... 27, 2014 Aspirus Wausau Hospital today ... US with Buzz™ Digital O.R. at Aspirus Wausau Hospital, ... 13 new operating rooms will be Buzz, a centralized ... integrative system supports planning, navigation, imaging and communications connectivity. ... of intuitive software and hardware all controlled from the ...
(Date:8/27/2014)... August 27, 2014 SCOTT Sports ... Park, Utah’s first indoor mountain bike and BMX park. ... park-style bikes in both adult and youth sizes for the ... operated a distribution warehouse in Ogden, Utah, recently moved its ... , “We are proud to be a partner with the ...
(Date:8/27/2014)... Steven Reinberg HealthDay Reporter ... hormone used to reduce the need for blood transfusions might ... suggests. Synthetic erythropoietin (EPO), which stimulates red blood cell ... preterm birth, said lead researcher Dr. Petra Huppi, a professor ... in Switzerland. "The real test of whether EPO protects ...
Breaking Medicine News(10 mins):Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 2Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 3Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 4Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 5Health News:IQ Formulations Contributes Sizeable Donation to Cystic Fibrosis Foundation 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 3Health News:SCOTT Sports to Sponsor Wasatch Indoor Bike Park 2Health News:Hormone Might Help Preemies' Brains 2Health News:Hormone Might Help Preemies' Brains 3
... WASHINGTON, DCThrough the identification of a gene,s impact on ... Center continue to make progress in understanding the ... repair of white matter, known as myelination. The study, ... of The Journal of Neuroscience , identified ...
... of the 5.3 million men and women seen in Department ... that use of cocaine is predictive of open-angle glaucoma, the ... that after adjustments for race and age, current and former ... Men with open-angle glaucoma also had significant exposures to amphetamines ...
... found that patients had little or no control over their ... care, but a new study shows that this has changed ... with health coverage that includes a high deductible and either ... their costs even after they initiated care. ...
... THURSDAY, Sept. 29 (HealthDay News) -- The bellowing of male ... researchers report. They found that the largest koalas produce ... males that they,re the biggest dudes in the neighborhood. ... few animals with a descended larynx, which makes the vocal ...
... their everyday lives and with support from partners can continue ... of the preliminary findings of a two-year research project funded ... married couples living with dementia make decisions on a daily ... over issues such as what to eat or wear, as ...
... , WEDNESDAY, Sept. 28 (HealthDay News) -- Cancer patients ... can have serious side effects and even mean the ... crucial that patients insist doctors use plain language ... associate professor of internal medicine at the University of ...
Cached Medicine News:Health News:Children's National researchers make breakthrough in understanding white matter development 2Health News:Children's National researchers make breakthrough in understanding white matter development 3Health News:Cocaine users have 45 percent increased risk of glaucoma 2Health News:Study finds consumers may have more control over health costs than previously thought 2Health News:Study finds consumers may have more control over health costs than previously thought 3Health News:Living with dementia and making decisions 2Health News:Cancer Patients Should Ask Doctors to Use Simple Terms 2
(Date:8/27/2014)... 27, 2014 /CNW/ - Covalon Technologies Ltd. (the "Company" or ... following financial results for its third quarter of fiscal 2014: ... , Revenue of $1,291,378, a 13% decrease over ... loss for the quarter of $240,156 compared to net income ... For the nine months ended June 30, ...
(Date:8/27/2014)... Aug. 27, 2014 IRIDEX Corporation (NASDAQ: ... H. Mackaness is scheduled to make an investor presentation ... 2:55 p.m. Eastern Time on Wednesday, September 3, in New ... the investor presentation will be available in the Investors section ... About IRIDEX IRIDEX Corporation was founded in ...
(Date:8/27/2014)... CITY, Calif. , Aug. 27, 2014  AcelRx ... pharmaceutical company focused on the development and commercialization of ... pain, today announced that senior management will be participating ... presenting at the Morgan Stanley Global Healthcare Conference.  Details ... FBR Healthcare One on One Conference Date: Wednesday September ...
Breaking Medicine Technology:Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 2AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 3
Instrument Cover for Vibratome....
These specialty razor blades are feather thin and very sharp. Most users have found an increased quality level in Vibratome sections with these blades....
This is a perfect tool for retrieving free floating sections from the Vibratome bath....
The care package includes a spare motor, fuse, Spare Fluorescent Bulb, additional Vibratome Feather Blades, Specimen Adhesive, Specimen Mounting Blocks, and a Specimen Tray....
Medicine Products: